Daiichi Sankyo Halts Late-Stage Trial for Lung Cancer Candidate

Daiichi Sankyo pulled the plug on a Phase 3 trial of its non-small cell lung cancer candidate after an independent data monitoring committee found it missed its primary endpoint.

The committee recommended that Daiichi Sankyo discontinue the second Phase 3 study because patritumab failed to show clinically relevant tumor growth control in an initial Phase 3 trial.

The company plans to release the data from the analysis at an upcoming scientific meeting, a spokeswoman said. After further review of this analysis, Daiichi Sankyo will determine next steps for patritumab.